Lexicon Pharmaceuticals Q3 2024 Earnings Preview
Lexicon Pharmaceuticals (NASDAQ:LXRX) is scheduled to announce Q3 earnings results on Tuesday, November 12th, after market ...
bovnews42m
Lexicon Pharmaceuticals Inc (LXRX) Stock Price Reaches $1.27: What Factors Are Influencing This Level?
On Monday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a modest uptick, ending the day at $1.27 which represents no change from the prior close of of $1.27. The stock opened at $1.26 and touched a ...
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for ...
Preview: Lexicon Pharmaceuticals's Earnings
Analysts are estimating that Lexicon Pharmaceuticals will report an earnings per share (EPS) of $-0.16. The announcement from Lexicon Pharmaceuticals is eagerly anticipated, with investors seeking ...
The Globe and Mail4h
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
Lexicon Pharmaceuticals, Inc. - GlobeNewswire - Wed Nov 6, 7:00AM CST THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its ...
bovnews2d
Why Did Lexicon Pharmaceuticals Inc (LXRX) Plummet? Key Factors Explained
On Friday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $1.27 which represents a decrease of $-0.03 or -2.31% from the prior close of $1.3. The stock opened at $1.3 and ...
Stocktwits on MSN11d
Lexicon Pharmaceuticals Loses Over A Third Of Its Market Cap Post FDA Vote On Drug: Retail Sentiment Sours
Shares of Lexicon Pharmaceuticals tanked nearly 33.6% as of 11:30 am ET after the drug company’s sotagliflozin drug candidate received a negative vote by a US Food and Drug Administration (FDA) panel, ...
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes
Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' ...
BioSpace11d
Lexicon Loses FDA Adcomm Vote on Insulin Adjunct for Patients With Type 1 Diabetes
While an FDA advisory committee saw signals of efficacy for Lexicon Pharmaceuticals’ sotagliflozin, the panel of external ...
Nasdaq7d
The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals
Lexicon Pharmaceuticals (NASDAQ:LXRX) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent ...
Optimistic Buy Rating for Lexicon Pharmaceuticals Due to Positive Outlook on Sotagliflozin’s FDA Review
H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on LXRX stock, giving a Buy rating on October 17. Joseph ...
Yahoo Finance6d
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference.